BioNTech’s (BNTX) Sell (D-) Rating Reiterated at Weiss Ratings

Weiss Ratings reaffirmed their sell (d-) rating on shares of BioNTech (NASDAQ:BNTX) in a research report report published on Tuesday morning,Weiss Ratings reports.

A number of other equities research analysts have also issued reports on BNTX. Morgan Stanley dropped their target price on shares of BioNTech from $133.00 to $131.00 and set an “overweight” rating for the company in a report on Friday, October 10th. Wells Fargo & Company set a $150.00 price target on shares of BioNTech and gave the stock an “overweight” rating in a research report on Tuesday, August 5th. Bank of America upped their price objective on shares of BioNTech from $126.00 to $134.00 and gave the company a “buy” rating in a research note on Tuesday, August 5th. JPMorgan Chase & Co. raised their target price on shares of BioNTech from $116.00 to $121.00 and gave the stock a “neutral” rating in a research note on Monday, September 22nd. Finally, HC Wainwright restated a “buy” rating and set a $136.00 target price on shares of BioNTech in a report on Monday, September 8th. Ten analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $134.32.

BioNTech Trading Up 0.7%

BNTX stock opened at $105.08 on Tuesday. BioNTech has a 12-month low of $81.20 and a 12-month high of $129.27. The business’s 50-day moving average is $103.89 and its 200 day moving average is $103.78. The company has a current ratio of 8.61, a quick ratio of 8.48 and a debt-to-equity ratio of 0.01. The stock has a market cap of $25.26 billion, a price-to-earnings ratio of -65.67 and a beta of 1.45.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($1.41) by ($0.19). BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The firm had revenue of $306.46 million during the quarter, compared to analysts’ expectations of $161.26 million. During the same quarter last year, the business earned ($3.36) EPS. The business’s revenue was up 102.6% compared to the same quarter last year. BioNTech has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that BioNTech will post -3.88 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC purchased a new stake in BioNTech in the fourth quarter valued at $238,000. Prosperity Wealth Management Inc. acquired a new stake in shares of BioNTech during the 1st quarter worth about $300,000. Goodman Advisory Group LLC purchased a new stake in BioNTech in the 1st quarter valued at about $105,000. Vontobel Holding Ltd. raised its holdings in BioNTech by 2.3% in the 1st quarter. Vontobel Holding Ltd. now owns 21,882 shares of the company’s stock valued at $1,993,000 after buying an additional 497 shares during the period. Finally, OneDigital Investment Advisors LLC acquired a new position in BioNTech in the first quarter valued at about $288,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.